<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03848208</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-CYT-08</org_study_id>
    <nct_id>NCT03848208</nct_id>
  </id_info>
  <brief_title>A Single Dose-escalation Study of Cytisine in Adult Smokers</brief_title>
  <official_title>A Phase I, Double-blind, Randomized, Placebo-controlled, Single Dose-escalation Study to Evaluate the Tolerability and Safety of Cytisine in Adult Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achieve Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achieve Life Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are:

        1. To assess the tolerability and safety of cytisine as a single oral dose.

        2. To define the Cmax levels associated to the occurrence of dose-limiting adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Actual">September 12, 2019</completion_date>
  <primary_completion_date type="Actual">September 8, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs), Serious AEs, and AEs Leading to Study Discontinuation</measure>
    <time_frame>Through Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1: Pre-dose (within 30 minutes prior to dosing), 15, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours (+/-2 minutes) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Time to Occurrence of Cmax (Tmax)</measure>
    <time_frame>Day 1: Pre-dose (within 30 minutes prior to dosing), 15, 30, 40, 50 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, and 3 hours (+/-2 minutes) post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Cytisine 6.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Cytisine 9.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Cytisine 12.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Cytisine 15.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Cytisine 18.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: Cytisine 21.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: Cytisine 24.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8: Cytisine 27.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9: Cytisine 30.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytisine</intervention_name>
    <description>cytisine film-coated oral tablet</description>
    <arm_group_label>Cohort 1: Cytisine 6.0 mg</arm_group_label>
    <arm_group_label>Cohort 2: Cytisine 9.0 mg</arm_group_label>
    <arm_group_label>Cohort 3: Cytisine 12.0 mg</arm_group_label>
    <arm_group_label>Cohort 4: Cytisine 15.0 mg</arm_group_label>
    <arm_group_label>Cohort 5: Cytisine 18.0 mg</arm_group_label>
    <arm_group_label>Cohort 6: Cytisine 21.0 mg</arm_group_label>
    <arm_group_label>Cohort 7: Cytisine 24.0 mg</arm_group_label>
    <arm_group_label>Cohort 8: Cytisine 27.0 mg</arm_group_label>
    <arm_group_label>Cohort 9: Cytisine 30.0 mg</arm_group_label>
    <other_name>Tabex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo oral tablet</description>
    <arm_group_label>Cohort 1: Placebo</arm_group_label>
    <arm_group_label>Cohort 2: Placebo</arm_group_label>
    <arm_group_label>Cohort 3: Placebo</arm_group_label>
    <arm_group_label>Cohort 4: Placebo</arm_group_label>
    <arm_group_label>Cohort 5: Placebo</arm_group_label>
    <arm_group_label>Cohort 6: Placebo</arm_group_label>
    <arm_group_label>Cohort 7: Placebo</arm_group_label>
    <arm_group_label>Cohort 8: Placebo</arm_group_label>
    <arm_group_label>Cohort 9: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet ALL of the following criteria to be eligible for inclusion into the
        study:

          1. Free written informed consent prior to any procedure required by the study.

          2. Male or female subjects, age ≥18 years, at the time of signing the informed consent.

          3. Current daily cigarette smokers (averaging at least 10 cigarettes per day in the past
             30 days).

          4. Expired air carbon monoxide (CO) ≥10 ppm.

          5. Able to swallow multiple tablets at one time.

          6. Able to fully understand, comply with all study requirements.

        Exclusion Criteria:

        Subjects meeting ANY of the following exclusion criteria will NOT be eligible for inclusion
        into the study at screening.

          1. Known hypersensitivity to cytisine or any of the excipients.

          2. Known severe hypersensitivity to any other drug.

          3. Positive urinary drugs of abuse screen, determined within 28 days before
             cytisine/placebo dosing.

          4. Positive ethanol breath test.

          5. Clinically significant abnormal serum chemistry, hematology, coagulation or urinalysis
             values within 28 days of randomization (i.e. requiring treatment or monitoring).

          6. Clinically significant abnormalities in 12-lead ECG determined after minimum of 5
             minutes in supine position within 28 days of randomization (i.e. requiring treatment
             or further assessment).

          7. Body Mass Index (BMI) classification for being underweight (&lt;18.5 kg/m2) or having
             ≥Class 2 obesity (≥35 kg/m2).

          8. History of acute myocardial infarction, unstable angina, stroke, cerebrovascular
             incident, cardiac arrhythmia, or hospitalization for congestive heart failure.

          9. Blood pressure ≥160/100 mmHg, measured on the dominant arm, after at least 3 minutes
             in supine position.

         10. Creatinine clearance (CrCl) &lt;80 mL/min (estimated with the Cockroft-Gault equation).

         11. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;2.0 x the upper
             limit of normal (ULN).

         12. Any inability to comply with study restrictions (See Section 9)

         13. Any inability or difficulty in fasting.

         14. Difficulty in donating blood on either arm.

         15. If woman of childbearing potential, positive result in serum beta-hCG pregnancy test.

         16. Women who are breast-feeding.

         17. Subjects who do not agree to use acceptable methods of birth control during the study
             (See Section 9.4).

         18. Participation in a clinical study with an investigational drug within the previous 2
             months.

         19. Participation in more than 2 clinical trials within the previous 12 months.

         20. Any other reason that the investigator views the subject should not participate or
             would be unable to fulfill the requirements for the study.

             Subjects meeting ANY of the following exclusion criteria will NOT be eligible for
             inclusion into the study at admission to each cohort.

         21. Any recent disease or condition or treatment that, according to the Investigator,
             would put the subject at undue risk due to study participation.

         22. Positive urinary drugs of abuse screen.

         23. Positive ethanol breath test.

         24. If female of childbearing potential, positive result in urine beta-hCG pregnancy test.

         25. Any other reason that the investigator views the subject should not participate or
             would be unable to fulfill the requirements for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlene Fonseca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital da Prelada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BlueClinical</name>
      <address>
        <city>Porto</city>
        <zip>4250-449</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 19, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

